Apalutamide OK'd for Some Prostate Cancers.
Sign Up to like & getrecommendations! Published in 2018 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-012
Abstract: The FDA approved the antiandrogen apalutamide for the treatment of men with nonmetastatic, castration-resistant prostate cancer, the first drug for these patients greenlighted by the agency. Data from the definitive trial of apalutamide, presented at… read more here.
Keywords: drug; apalutamide prostate; prostate cancers;